Table 3.

Most common amino acid substitutions and genotypes/subtypes in DAA nonresponding HCV infected patients[52,59,60]

DAAs approved by FDA	Category of DAAs	Most common amino acid substitutions detected in HCV infected patients who failed to achieve SVR	Most common HCV genotype/subtype associated with SVR failure
Boceprevir	NS3/4A protease inhibitor	V36M, T54S, R155K	1a
		T54A/S, V55A, A156S, V170A	1b
Telaprevir	NS3/4A protease inhibitor	V36M, R155K	1a
		V36A, T54A, A156S	1b
Simeprevir	NS3/4A protease inhibitor	R155K, D168E/V	1a
		Q80R, D168E/V	1b
Paritaprevir	NS3/4A protease inhibitor	D168A/V/Y	1a
		Y56H, D168V	1b
		D168V	4d
Asunaprevir	NS3/4A protease inhibitor	R155K, D168E	1a
		D168E/V/Y	1b
Vaniprevir	NS3/4A protease inhibitor	R155K, D168T/V/Y	1a
		D168H/T/V	1b
NS5A inhibitor	M28T, Q30E/H/R, L31M, H58D, Y93H/N	1a
	L31M/V, Y93H	1b
	Q30H/S	4
Ledipasvir	NS5A inhibitor	Q30E/R, L31M, Y93C/H/N	1a
		Y93H	1b
Ombitasvir	NS5A inhibitor	M28V, Q30R	1a
		Y93H	1b
		L28V	4d
Sofosbuvir	NS5B nucleotide polymerase inhibitor	S282T	2
		L159F, V321A	3
		C316N/H/F	1b
Dasabuvir	NS5B non-nucleoside polymerase inhibitor	M414T, S556G	1a
		S556G	1b
Beclabuvir	NS5B non-nucleoside polymerase inhibitor	A421V, P495L/S	1a